Pan-immune-inflammation value as a novel prognostic biomarker for digestive system cancers - a meta-analysis

Q: What biomarker does the meta-analysis focus on?

The study evaluates the pan-immune-inflammation value (PIV) as a prognostic biomarker reflecting immune-inflammatory response in digestive system cancers.

Q: How was the evidence gathered and analyzed?

A meta-analysis was conducted using search results up to June 2024, extracting PIV data and hazard ratios for multiple survival outcomes using STATA 14.0.

Q: What is the prognostic implication of high PIV levels?

High PIV levels are associated with significantly poorer prognosis, including worse overall survival and other survival endpoints such as PFS, DFS, RFS, and CSS.

Sep 21, 2026

Uploaded by Seraphina

Digestive system cancers create major global health burdens with persistently high incidence and mortality. Inflammation is central to cancer progression, motivating the search for dependable prognostic indicators. This meta-analysis assesses the pan-immune-inflammation value (PIV) as a measure of immune-inflammatory response and evaluates whether higher PIV corresponds to worse survival across digestive system malignancies.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Abstract

Introduction

Background and rationale

Role of inflammation and immune response

Yu etal. World Journal of Surgical Oncology (2024) 22:306 [https://doi.org/10.1186/s12957-024-03595-z](https://doi.org/10.1186/s12957-024-03595-z) World Journal of Surgical Oncology REVIEW Open Access Pan-immune-inflammation value as a novel prognostic biomarker for digestive system cancers: a meta-analysis Dongli Yu 1†, Jingting Liu2†, Chunyan Meng 1, Baoqing Liu 1 and Jianhua Liao 1* Abstract Background Digestive system cancers pose a significant global health challenge with high incidence and mortality rates. Inflammation is a key factor in cancer progression, necessitating reliable prognostic indicators. The pan-immune-inflammation value (PIV), as a new biomarker of immune-inflammatory response, has emerged as a potential prognostic biomarker for cancers. Methods We performed a meta-analysis to evaluate the prognostic significance of PIV in digestive system cancers. Our search, up to June 2024, included 20 studies from 19 articles with 5037 patients. We extracted and analyzed data on PIV levels and assessed hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS) using STATA 14.0. Results Our analysis found that high PIV levels were significantly associated with poor prognosis in patients with digestive system cancers. Specifically, high PIV was linked to shorter OS (HR = 2 . 039, P < 0. 001), PFS (HR = 1 . 877, P = 0 . 028), DFS (HR = 1 . 624, P = 0 . 005), RFS (HR = 2 . 393, P = 0 . 037), and CSS (HR = 2 . 053, P < 0. 001) . Additionally, the adverse prognostic impact of high PIV on OS was consistent across different cancer types, including digestive tract, colorectal, esophageal, and hepatobiliary pancreatic cancers. Although some heterogeneity was observed, sensitivity and bias analyses confirmed the reliability of these findings. Conclusions PIV was a valuable and practical prognostic marker for digestive system cancers, providing significant predictive value across multiple survival metrics. Its simplicity and minimal invasiveness nature support its potential integration into routine clinical practice. Keywords Pan-immune-inflammation value, Cancer, Meta-analysis, Prognosis, Biomarker †Dongli Yu and Jingting Liu contributed equally to this work. *Correspondence: Jianhua Liao [ljhsywzh@163.com](ljhsywzh@163.com) 1Department of Surgery, Zhejiang Hospital, 12 Lingyin Road, Zhejiang 310013, China 2Department of Health management, Sir Run Run Shaw International Medical Centre, 9 Jingtan Road, Hangzhou 310000, Zhejiang, China © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/. Yu et al. World Journal of Surgical Oncology (2024) 22:306 Introduction Malignant tumors have long been a major health issue affecting people worldwide. Despite significant advancements in various areas of research in recent years, which have improved the conditions for some individual

FAQs

What biomarker does the meta-analysis focus on?

The study evaluates the pan-immune-inflammation value (PIV) as a prognostic biomarker reflecting immune-inflammatory response in digestive system cancers.

How was the evidence gathered and analyzed?

A meta-analysis was conducted using search results up to June 2024, extracting PIV data and hazard ratios for multiple survival outcomes using STATA 14.0.

What is the prognostic implication of high PIV levels?

High PIV levels are associated with significantly poorer prognosis, including worse overall survival and other survival endpoints such as PFS, DFS, RFS, and CSS.

Sep 21, 2026

Uploaded by Seraphina